Evidence map›Paper›PMID 41611249›Full record

ArticlePediatric dermatology

Characterization of TNF-Alpha Inhibitor Induced Paradoxical Psoriasiform Dermatitis at a Single Center via Retrospective Chart Review.

Muayad M Shahin, Emily S Gorell, Mariam Iqneibi, Qin Sun, Hermine I Brunner, Jennifer Hellmann, Kalyani S Marathe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muayad M ShahinUniversity of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0002-1715-0254
Emily S GorellDepartment of Dermatology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0002-2813-3089
Mariam IqneibiDivision of Dermatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.ORCID https://orcid.org/0009-0003-8268-0408
Qin SunDivision of Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Hermine I BrunnerDivision of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0001-9478-2987
Jennifer HellmannDivision of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Kalyani S MaratheUniversity of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Funding

Pediatric musculOskeletal & RheumaTology Innovation COre center (PORTICO)P30AR076316 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI BRUNNER, HERMINE I · 2019 to 2023
$3.4M
NIAMS Core Center P30AR076316NIAMS NIH HHS P30 AR076316Stella and Carey Wamsley Charitable Trust
6 · The paper itself

Abstract

Tumor necrosis factor-alpha inhibitors (TNFi) are used to treat various autoimmune diseases but can induce paradoxical psoriasiform dermatitis (PD) in a subset of patients. This retrospective chart review aimed to identify risk factors impacting PD severity in 70 pediatric patients at a single center. Forty patients (57.1%) discontinued their initial TNFi: 12/40 (30.0%) switched to another TNFi, with 4/12 (33.3%) experiencing PD recurrence, while 25/40 (62.5%) switched medication classes. Female sex was associated with increased use of high-potency topical steroids (p = 0.01), suggesting more severe disease. Juvenile idiopathic arthritis (p = 0.02), older age (p < 0.01), and concomitant immunomodulator use (p = 0.04) were associated with a longer latency period before PD development.

Indexed as

Drug EruptionsPsoriasisTumor Necrosis Factor-alphaAdolescentArthritis, JuvenileChildChild, PreschoolFemaleHumansMaleRetrospective StudiesRisk FactorsSeverity of Illness IndexTumor Necrosis Factor-alphabiologicsdrug‐inducedinflammatory bowel diseasejuvenile arthritisparadoxical psoriasispsoriasiform dermatitispsoriasisTNF inhibitor‐induced psoriasistumor necrosis factor‐alpha inhibitor

Identifiers

PMID41611249
PMCPMC12976799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.